StemCell Therapy

Advertisement

Shares last traded at $93.95 barely above $87.37, the 50 day moving average and which is well above the 200 day moving average of $61.78. The 50 day moving average went up by +7.53% whereas the 200 day average was up by +52.06%. 820K shares changed hands by the end of trading on Friday. Overall, volume was down 80.71% under the stocks normal daily volume.

Traders are more bullish on Puma Biotechnology Inc of late looking at the fall in short interest. The firm had a fall in short interest between July 31, 2017 and August 15, 2017 of -0.12%. Short interest decreased 7,361 over that timeframe. The days to cover decreased to 6.0 and the percentage of shorted shares was 0.17% on August 15.

Here is the rundown on market activity for Puma Biotechnology Inc (NASDAQ:PBYI). Richard Paul Bryce, SR VP, CLINICAL RESEARCH & DEV sold $435,500 worth of shares at an average price of $87.10 on July 3rd. Bryce now owns $2,546,543 of stock as recorded in a recent Form 4 SEC filing.

Here are a few other firms who have also updated their positions. Janus Capital Management LLC divested its stake by shedding 2,714 shares a decrease of 0.1% from 12/31/2016 to 03/31/2017. Janus Capital Management LLC currently owns 2,209,599 shares worth $82,195,000. The total value of its holdings increased 21.0%. Rock Springs Capital Management Lp expanded its investment by buying 91,500 shares an increase of 96.8% as of 06/30/2017. Rock Springs Capital Management Lp claims 186,000 shares valued at $16,256,000. The value of the position overall is up by 362.5%.

Ghost Tree Capital, LLC reduced its holdings by selling 75,000 shares a decrease of 33.3% in the quarter. Ghost Tree Capital, LLC now holds 150,000 shares with a value of $13,110,000. The value of the position overall is up by 56.6%. As of the end of the quarter Graticule Asia Macro Advisors LLC had sold 6,200 shares trimming its holdings by 13.4%. The value of the investment in (PBYI) went from $1,726,000 to $3,514,000 a change of 103.6% quarter over quarter.

July 18 investment analysts at Credit Suisse maintained a stock rating of Outperform and raised the price target to $118.00 from $111.00.

In the market the company is trading up by 1.57% since yesterdays close of $92.5. In the last earnings report the EPS was $-8.14 and is expected to be $-8.68 for the current year with 37,205,000 shares outstanding. Analysts expect next quarters EPS to be $-2.09 and the next full year EPS is projected to be $-4.71.

Puma Biotechnology, Inc., launched on September 15, 2010, is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to the three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Its neratinib has clinical application in the treatment of several other cancers as well, including non-small cell lung cancer (NSCLC), and other tumor types that over-express or have a mutation in HER2..

Originally posted here:
Puma Biotechnology Inc (NASDAQ:PBYI) Stock Closed 7.5% Above Its 50 Day Average - Modern Readers

This entry was posted on September 4, 2017 at 11:47 am and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |